Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vaxcyte, Inc. - Common Stock
(NQ:
PCVX
)
65.08
-8.74 (-11.84%)
Delayed Quote
Updated: 10:09 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaxcyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Vaxcyte to Present at Upcoming Investor Conferences
October 31, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
October 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Preview: Vaxcyte's Earnings
↗
February 24, 2023
Via
Benzinga
Expert Ratings for Vaxcyte
↗
January 03, 2023
Via
Benzinga
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
July 11, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
May 03, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
MarketBeat Week in Review – 4/17 - 4/21
April 22, 2023
Markets ended the week on a down note as further evidence that the markets are likely to continue to bounce around but could get a jolt from earnings next week
Via
MarketBeat
Topics
Economy
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 21, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
↗
April 20, 2023
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...
Via
Benzinga
Vaxcyte Announces Pricing of $500 Million Public Offering
April 19, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
April 18, 2023
When a biotech company delivers chart-busting news, more often follows. In a space that can be like throwing darts, Wall Street has bullseyes on Vaxcyte, Inc.
Via
MarketBeat
Why Vaxcyte Stock Is Sliding After Hours
↗
April 17, 2023
Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a
Via
Benzinga
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 17, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
↗
April 18, 2023
Via
Benzinga
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
April 17, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
April 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
March 30, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
February 21, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 27, 2023
↗
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
January 05, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
↗
January 03, 2023
Via
Benzinga
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
↗
January 03, 2023
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
